

Cover Story
Free
By Matthew Bin Han Ong
The contract for operations and technical support at the Frederick National Laboratory for Cancer Research could be accepting proposals as early as next month—but NCI advisors said they are hoping to slow the recompetition process to reform the laboratory's mission.
In Brief


Drugs & Targets
Trending Stories
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Pam Bondi diagnosed with thyroid cancer
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- As FDA’s wheels almost entirely come off, NCI remains sturdy—a cancer moonshot may even be on the horizon
- UK Markey’s Denise Fabian: Theranostics lets us pair a diagnostic with a radioactive therapeutic that target the same molecule
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe













